Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines

Abstract

Significance The COVID-19 pandemic caused by SARS-CoV-2 infection has led to more than 840,000 deaths worldwide as of August 31, 2020. Unfortunately, no licensed vaccine or specific treatment is available right now. Herein, we report a decoy nanoparticle against COVID-19. The decoy nanoparticles were constructed by fusing cell membrane nanovesicles derived from genetically engineered cells, which stably express SARS-CoV-2 receptor ACE2, and human monocytes, which display abundant cytokine receptors. By competing with host cells, these nanodecoys efficiently adsorb viruses and inflammatory cytokines such as IL-6 and GM-CSF. These two functionalities allow effective intervention of viral infection and its associated immune disorder, presenting a promising therapeutic strategy for COVID-19 and other potential epidemics.

References 40

1. 1.

   S. Jiang., A distinct name is needed for the new coronavirus. Lancet 395, 949 (2020 ).

   Not in our library10.1016/s0140-6736(20)30419-0

2. 2.

   C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020 ).

   Not in our library10.1016/s0140-6736(20)30185-9

3. 3.

   N. Zhu.; China Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020 ).

   Not in our library10.1056/nejmoa2001017

4. 4.

   J. M. Sanders, M. L. Monogue, T. Z. Jodlowski, J. B. Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. J. Am. Med. Assoc. 323, 1824–1836 (2020 ).

   Not in our library10.1001/jama.2020.6019

5. 5.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
6. 6.

   M. Hoffmann., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020 ).

   Not in our library10.1016/j.cell.2020.02.052

7. 7.
   Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein · 2020

   No notice
8. 8.

   M. Merad, J. C. Martin, Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020 ).

   Not in our library10.1038/s41577-020-0331-4

9. 9.

   J. B. Moore, C. H. June, Cytokine release syndrome in severe COVID-19. Science 368, 473–474 (2020 ).

   Not in our library10.1126/science.abb8925

10. 10.

    C. Huang., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020 ).

    Not in our library10.1016/s0140-6736(20)30183-5

11. 11.

    X. Cao, COVID-19: Immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269–270 (2020 ).

    Not in our library10.1038/s41577-020-0308-3

12. 12.

    B. N. Williamson., Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 585, 273–276 (2020 ).

    Not in our library10.1038/s41586-020-2423-5

13. 13.

    Y. Wang., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395, 1569–1578 (2020 ).

    Not in our library10.1016/s0140-6736(20)31022-9

14. 14.

    E. H. Choy., Translating IL-6 biology into effective treatments. Nat. Rev. Rheumatol. 16, 335–345 (2020 ).

    Not in our library10.1038/s41584-020-0419-z

15. 15.

    F. M. Lang, K. M. C. Lee, J. R. Teijaro, B. Becher, J. A. Hamilton, GM-CSF-based treatments in COVID-19: Reconciling opposing therapeutic approaches. Nat. Rev. Immunol. 20, 507–514 (2020 ).

    Not in our library10.1038/s41577-020-0357-7

16. 16.
    Effective treatment of severe COVID-19 patients with tocilizumab · 2020

    No notice
17. 17.
    Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients · 2020

    No notice
18. 18.

    S. Thamphiwatana., Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl. Acad. Sci. U.S.A. 114, 11488–11493 (2017 ).

    Not in our library10.1073/pnas.1714267114

19. 19.

    B. D. Henry., Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat. Biotechnol. 33, 81–88 (2015 ).

    Not in our library10.1038/nbt.3037

20. 20.

    C.-M. J. Hu, R. H. Fang, J. Copp, B. T. Luk, L. Zhang, A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 8, 336–340 (2013 ).

    Not in our library10.1038/nnano.2013.54

21. 21.

    J. M. Richner., Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125.e10 (2017 ).

    Not in our library10.1016/j.cell.2017.02.017

22. 22.

    P. Zhang., Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc. Natl. Acad. Sci. U.S.A. 112, E6129–E6138 (2015 ).

    Not in our library10.1073/pnas.1505799112

23. 23.

    V. Cagno., Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat. Mater. 17, 195–203 (2018 ).

    Not in our library10.1038/nmat5053

24. 24.

    J. A. Jackman., Therapeutic treatment of Zika virus infection using a brain-penetrating antiviral peptide. Nat. Mater. 17, 971–977 (2018 ).

    Not in our library10.1038/s41563-018-0194-2

25. 25.

    J. Wang., Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367, eaau0810 (2020 ).

    Not in our library10.1126/science.aau0810

26. 26.

    M. D. Keller., Decoy exosomes provide protection against bacterial toxins. Nature 579, 260–264 (2020 ).

    Not in our library10.1038/s41586-020-2066-6

27. 27.

    P. Zhang., Genetically engineered liposome-like nanovesicles as active targeted transport platform. Adv. Mater. 30, 1705350 (2018 ).

    Not in our library10.1002/adma.201705350

28. 28.

    Q. Zhang., Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett. 20, 5570–5574 (2020 ).

    Not in our library10.1021/acs.nanolett.0c02278

29. 29.

    L. Rao, R. Tian, X. Chen, Cell-membrane-mimicking nanodecoys against infectious diseases. ACS Nano 14, 2569–2574 (2020 ).

    Not in our library10.1021/acsnano.0c01665

30. 30.

    L. Rao., A biomimetic nanodecoy traps Zika virus to prevent viral infection and fetal microcephaly development. Nano Lett. 19, 2215–2222 (2019 ).

    Not in our library10.1021/acs.nanolett.8b03913

31. 31.

    Q. Zhang., Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat. Nanotechnol. 13, 1182–1190 (2018 ).

    Not in our library10.1038/s41565-018-0254-4

32. 32.

    Y. He., Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 24, 5498–5508 (2006 ).

    Not in our library10.1016/j.vaccine.2006.04.054

33. 33.

    L. Rao., Platelet–leukocyte hybrid membrane-coated immunomagnetic beads for highly efficient and highly specific isolation of circulating tumor cells. Adv. Funct. Mater. 28, 1803531 (2018 ).

    Not in our library

34. 34.
    Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion · 2020

    No notice
35. 35.

    L. Bao., The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833 (2020 ).

    Not in our library10.1038/s41586-020-2312-y

36. 36.
    Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 · 2020

    No notice
37. 37.

    T. Hirotani., The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J. Immunol. 174, 3650–3657 (2005 ).

    Not in our library10.4049/jimmunol.174.6.3650

38. 38.

    C.-M. J. Hu., Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 108, 10980–10985 (2011 ).

    Not in our library10.1073/pnas.1106634108

39. 39.

    D. Chu, J. Gao, Z. Wang, Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano 9, 11800–11811 (2015 ).

    Not in our library10.1021/acsnano.5b05583

40. 40.

    A. Nel, T. Xia, L. Mädler, N. Li, Toxic potential of materials at the nanolevel. Science 311, 622–627 (2006 ).

    Not in our library10.1126/science.1114397

Cited by papers we hold 4

• Translational medicine for acute lung injury · 2024
  No notice
• Recent applications of immunomodulatory biomaterials for disease immunotherapy · 2022
  No notice
• Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation · 2021
  No notice
• Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.